Tvardi Therapeutics (NASDAQ:TVRD) Stock Rating Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a sell rating to a strong sell rating in a research note published on Sunday,Wall Street Zen reports.

Other analysts also recently issued reports about the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, October 2nd. UBS Group upgraded Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective on the stock in a research note on Wednesday, July 8th. Raymond James Financial raised shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price objective for the company in a report on Wednesday, July 8th. Lucid Cap Mkts raised Tvardi Therapeutics to a “strong-buy” rating in a report on Tuesday, September 8th. Finally, Chardan Capital assumed coverage on Tvardi Therapeutics in a report on Tuesday, October 20th. They set a “buy” rating for the company. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.40.

Tvardi Therapeutics Price Performance

TVRD stock opened at $0.79 on Friday. The business has a fifty day moving average price of $1.38 and a 200-day moving average price of $2.77. The stock has a market capitalization of $10.58 million, a P/E ratio of -0.28 and a beta of 0.37. Tvardi Therapeutics has a 1-year low of $0.77 and a 1-year high of $5.69.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04). As a group, analysts anticipate that Tvardi Therapeutics will post -2.23 earnings per share for the current year.

Institutional Trading of Tvardi Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Susquehanna International Group LLP purchased a new stake in Tvardi Therapeutics during the 2nd quarter valued at approximately $63,000. BlackRock Inc. purchased a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at approximately $181,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Tvardi Therapeutics in the second quarter worth $34,000. 44.66% of the stock is currently owned by hedge funds and other institutional investors.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases involving abnormal STAT3 signaling. STAT3 is a protein that can contribute to tumor growth, treatment resistance and immune suppression, making it a potential target for drug development.

The company’s lead investigational product is TTI-101, an orally administered small-molecule inhibitor designed to block STAT3 activity. Tvardi is evaluating TTI-101 in clinical studies for solid tumors, including hepatocellular carcinoma and other advanced cancers.